Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hu3S193 consolidation in relapsing ovarian cancer
NCT01137071Phase 2Terminated
- Sponsor
- Recepta Biopharma
- Start
- Apr 2011
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of hu3S193 in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Recepta Biopharma. Started Apr 2011; status: terminated.
02
Drugs
hu3S193
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT01137071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01137071.